Azacitidine, Venetoclax, and Revumenib for Newly Diagnosed Older Adults with Acute Myeloid Leukemia (AML) and NPM1 mutation or KMT2A rearrangement: Updated Results from the Beat AML Consortium

Oral Presentation | Jun 12, 2025

Author

Zeidner JF, et al.

Congress

European Hematology Association Annual Congress 2025

Milan, Italy | June 12 – 15, 2025